



World Economic Forum selects Intercell as "Technology Pioneer 2009"

- » The World Economic Forum (WEF) awards innovators of the highest calibre, whose technologies have a deep impact on business and society
- » Intercell is the first Austrian company ever to be selected for this award
- » Vaccine innovator Intercell's technologies, its clear product focus and the company's solid financial situation qualified Intercell as a Technology Pioneer

Vienna (Austria), December 4, 2008 – Vaccine developer Intercell AG (VSE: ICLL) today announced that the World Economic Forum has selected Intercell as a Technology Pioneer 2009. The WEF selected 34 visionary global companies for their accomplishments as innovators of the highest calibre, and whose technologies will have a deep impact on business and society. To be selected as a Technology Pioneer, a company must be involved in the development of life-changing technology innovation and have the potential for long-term impact on business and society. In addition, it must demonstrate visionary leadership and show all the signs of being a long-standing market leader – and its technology must be proven commercially.

"We are very honoured to be awarded the title of Technology Pioneer 2009," said Gerd Zettlmeissl, CEO Intercell AG. "Intercell has indeed applied a pioneering spirit to focus its strength in immunology and biotechnology for the development of novel vaccines for the benefit of people across the globe," added Gerd Zettlmeissl.

Intercell AG is the first company in Austria to be awarded the title of Technology Pioneer by the WEF since the program started 10 years ago. The entire list of Technology Pioneers, together with their profiles and interviews with the executives of the selected companies, can be found at: <http://www.weforum.org/techpioneers>.

About Intercell AG

Intercell AG is a growing biotechnology company which focuses on the design and development of novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical need. The Company develops antigens and adjuvants which are derived from its proprietary technology platforms and has in-house GMP manufacturing capabilities. Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Merck & Co., Inc., Wyeth, Sanofi Pasteur, Kyowa Hakko Kirin, and the Statens Serum Institut.

The Company's leading product, a prophylactic vaccine against Japanese Encephalitis, is currently in the process of marketing approval in the US, Europe, Australia and Canada. Marketing approval in the US, Europe and Australia is expected for 2008.





The company's broad development pipeline includes a Travelers' Diarrhea vaccine (patch) in Phase II (start of Phase III expected in 2009), a Pseudomonas vaccine in Phase II, as well as an pandemic Influenza Vaccine Enhancement patch, a partnered S. aureus vaccine in Phase II and four products focused on infectious diseases in preclinical development.

Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

For more information please visit: www.intercell.com

Contact Intercell AG

Intercell AG

Lucia Malfent

Head of Corporate Communications

Campus Vienna Biocenter 3, A-1030 Vienna

P: +43-1-20620-1303

Mail to: LMalfent@intercell.com

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.